Highly Galactosylated Anti-CD20 (Ocrelizumab) Antibody (CAT#: BioBet-GA-048ZP) Datasheet

MS4A1

membrane spanning 4-domains A1

This gene encodes a member of the membranespanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a Blymphocyte surface molecule which plays a role in the development and differentiation of Bcells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

B1, S7, Bp35, CD20, CVID5, MS4A2, LEU-16,

Plasma membrane

Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.

b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).

Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody

Phosphorylated. Might be functionally regulated by protein kinase(s).

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Ocrelizumab

Humanized

Human

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets the CD20 marker on B lymphocytes and is therefore an immunosuppressive drug. It was developed by Genentech / Roche and was used for the treatment of multiple sclerosis.

Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)

Ocrelizumab is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B lymphocytes that express the CD20 antigen. B lymphocytes are known to promote the pathogenesis of MS by activating pro-inflammatory T cells and secreting pro-inflammatory cytokines. Ocrelizumab promotes cytotoxicity of antibody-dependent cells and complement-mediated cell lysis by binding to CD20-expressing B lymphocytes. Ocrelizumab may induce antibody-dependent cytotoxicity, involving macrophages, natural killer cells, and cytotoxic T cells that work together to cause cell death.

Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)